Mouse Monoclonal Antibody Production


Category
Service
Record History
Added on May 30, 2013 at 11:00 AM by Gribben, Erin
Modified on July 22, 2014 at 11:04 AM by Gribben, Erin
Shared with (contributions)
VAPR: Services Master

Our custom monoclonal project process is designed to produce novel antibodies against proteins, peptides, or other antigenic targets.  We work closely with each customer to maximize the success rate for obtaining antibodies that perform  in the assays of interest to the investigator.

Click here to find out more about the monoclonal antibody production process.


Timeline:

Project time lines vary depending on the response of animals to the particular antigen.  Our most important goal is to not enter into the more expensive and labor-intensive hybridoma generation stage until the chances of successfully generating useful hybridoma lines is high.  However, most projects enter the hybridoma generation stage after about 12-16 weeks from receipt of the protein. 

What we need:

Protein targets:  To begin the project we will generally need 1 mg of protein soluble in a non-toxic buffer at a concentration of 0.5 mg/ml (preferably 1mg/ml).  Before we enter the hybridoma generation at least another 0.5-1 mg is often required.  We can also assist you with production and purification of the necessary protein(s).  Click here to find out more about our protein services.

Peptide targets:  Due to the increased chances of success, we typically recommend utilizing protein antigens when possible.  However, in cases where this is not scientifically or practically possible, synthesized peptides are a suitable option.  VAPR can assist with both the design and generation of highly antigenic peptides.  

Monitoring:

To begin a project with VAPR please set up an account with us and submit a project proposal.  These allow us to gather information about the project in order to provide useful feedback.  They are also required to allow investigators to follow the progress of projects through our online tracking system.